Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 501–600 of 963
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1293652 · Cited by 9
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
Ludvigsson, J., Eriksson, L., Nowak, C., Teixeira, P. F., Widman, M., Lindqvist, A., Casas, R., Lind, M., & Hannelius, U. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061776 · Cited by 13
Self-citationLoretelli, C., Pastore, I., Lunati, M. E., Abdelsalam, A., Usuelli, V., Assi, E., Fiorina, E., Loreggian, L., Balasubramanian, H. B., Xie, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106709 · Cited by 9
New therapies towards a better glycemic control in youths with type 1 diabetes
Cardona‐Hernandez, R., Dovč, K., Biester, T., Ekhlaspour, L., Macedoni, M., Tauschmann, M., & Mameli, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106882 · Cited by 15
Corrales, P. J. P., Marcos, J. S., Gallardo, G. L., Moreno-Fernández, J., Antolín, S. H., López, I. Q., Zaballos, F. D. V., López, J. G., & Martínez, J. J. A. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.11.003 · Cited by 13
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.05.004 · Cited by 9
Nekoua, M. P., Fachinan, R., Fagninou, A., Alidjinou, E. K., Moutairou, K. A., Hober, D., & Yessoufou, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107868 · Cited by 8
Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi, S. M., Foster, N. C., Rash, C. J., Name, M. A. V., Tamborlane, W. V., Cengiz, E., Polsky, S., & Wagner, J. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.06.005 · Cited by 9
JENDLE, J. H., Adolfsson, P., & Pollock, N. W. (2020) · Diving and Hyperbaric Medicine Journal · doi:10.28920/dhm50.2.135-143 · Cited by 10
Fureman, A., Lilja, M., Lind, T., Särnblad, S., Bladh, M. K., & Samuelsson, U. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13217 · Cited by 12
“with well controlled Type 1 diabetes have a doubled risk of death from any cause as well as from cardiovascular causes compared to the general population, and the risks are several times higher among patients with poor glycemic control.(4)”
BackgroundDori‐Dayan, N., Cukierman‐Yaffe, T., Kedar, N., Zemet, R., Cohen, O., Mazaki‐Tovi, S., & Yoeli‐Ullman, R. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1993814 · Cited by 10
Denimal, D., Monier, S., Simoneau, I., Duvillard, L., Vergès, B. L., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01591-9 · Cited by 9
Arnold, R., Pussell, B. A., Kiernan, M. C., & Krishnan, A. V. (2015) · Muscle & Nerve · doi:10.1002/mus.25016 · Cited by 9
Chantzichristos, D., Persson, A., Miftaraj, M., Eliasson, B., Svensson, A.-M., & Johannsson, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02064 · Cited by 9
Self-citationDalla Libera, A., Toffanin, C., Drecogna, M., Galderisi, A., Pillonetto, G., & Cobelli, C. (2023) · APL Bioengineering · doi:10.1063/5.0145446 · Cited by 8
Bombaci, B., Passanisi, S., Lombardo, F., & Salzano, G. (2024) · Translational Pediatrics · doi:10.21037/tp-24-114 · Cited by 12
Sojo-Vega, L., Recasens, M., Martínez, J., Aguilera, A., Ayala, M., Admetlla, N., Pellicer, P., Blay, C., Fabregat, B., Esteve-Serra, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02455-0 · Cited by 10
Salle, L., Julla, J., Fagherazzi, G., Gourdy, P., Parente, E. B., Hanaire, H. P., Tatulashvili, S., Disse, E., Franc, S., Hadjadj, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02789-3 · Cited by 13
Bahrami, H. S. Z., Jørgensen, P. G., Hove, J. D., Dixen, U., Rasmussen, L. J. H., Eugen‐Olsen, J., Rossing, P. R., & Jensen, M. T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20108 · Cited by 9
Marinac, M., Rickels, M. R., Gaglia, J. L., O’Connell, P. J., Johnson, P., Piemonti, L., Schneider, B., Greenstein, J. L., Dutta, S., & Latres, E. (2025) · Diabetes · doi:10.2337/dbi24-0037 · Cited by 9
“I Like People to Treat Me Normally”: Barriers to Type 1 Diabetes Self-Management Among Adolescents
Momani, A., Callery, P., Lin, Y., Abdelkader, R. H., & Khalil, H. (2022) · Clinical Diabetes · doi:10.2337/cd20-0116 · Cited by 13
Cochran, B. J., Manandhar, B., & Rye, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_9 · Cited by 9
Tynjälä, A., Harjutsalo, V., Sigfrids, F. J., Groop, P., Gordin, D., & the FinnDiane Study Group (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01770-2 · Cited by 10
Skin Autofluorescence and Clinical Outcomes in Patients with Coronary Artery Disease
Kawamoto, H., Hanatani, S., Tsujita, K., Ruparelia, N., Chou, S., Kono, Y., & Nakamura, S. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64293 · Cited by 8
Donislecel: First Cellular Therapy to Treat Patients With Brittle Type 1 Diabetes
Giri, O., & Goldman, J. D. (2023) · Clinical Diabetes · doi:10.2337/cd23-0091 · Cited by 8
Hallström, S., Hirsch, I. B., Ekelund, M., Sofizadeh, S., Albrektsson, H., Dahlqvist, S., Svensson, J., & Lind, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0577 · Cited by 9
Self-citationSantos‐Pardo, I., Lagerqvist, B., Ritsinger, V., Witt, N., Norhammar, A., & Nyström, T. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.011 · Cited by 9
Taylor, G., Shaw, A., Smith, K., Capper, T. E., Scragg, J. H., Cronin, M., Bashir, A., Flatt, A. J., Campbell, M. D., Stevenson, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93886-2 · Cited by 9
Factores de riesgo cardiovascular
Ros, A. L., Al-Mahdi, E. A. R., Moya, R. R. M., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.011 · Cited by 16
What does the licensing of teplizumab mean for diabetes care?
Quinn, L. M., Swaby, R., Tatović, D., Narendran, P., Besser, R. E. J., & Dayan, C. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15071 · Cited by 7
Analysis of HbA1c on an automated multicapillary zone electrophoresis system
Rollborn, N., Åkerfeldt, T., Nordin, G., Xu, X. Y., Havelka, A. M., Hansson, L., & Larsson, A. O. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2016.1238507 · Cited by 8
Quirós, C., Viñals, C., Giménez, M., Roca, D., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.03.009 · Cited by 7
Akimoto, H., Fukuda-Kawaguchi, E., Duramad, O., Ishii, Y., & Tanabe, K. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9430473 · Cited by 8
“However, even while maintaining healthy BGLs, patients remain at risk of acute and late complications, including ischemic heart disease, retinopathy, and nephropathy [2, 3].”
BackgroundZwingli, G., Yerly, J., Mivelaz, Y., Stoppa‐Vaucher, S., Dwyer, A. A., Pitteloud, N., Stuber, M., & Hauschild, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228569 · Cited by 8
“Both disease duration and elevated glycated hemoglobin (HbA1c) levels are associated with increased cardiovascular morbidity and all-cause mortality [4].”
BackgroundSex hormone levels are not associated with progression of renal disease in male patients with T2DM
Feigerlová, E., Saulnier, P., Gourdy, P., Roussel, R., Halimi, J.-M., Gand, E., Dardari, D., Guerci, B., Sosner, P., Marre, M., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.012 · Cited by 8
Basu, A., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Schade, D. S., Wood, J., Alaupovic, P., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p080143 · Cited by 8
Eckel, R. H., & Hokanson, J. E. (2016) · Circulation · doi:10.1161/circulationaha.116.021654 · Cited by 8
Watso, J. C., Robinson, A. T., Singar, S., Cuba, J. N., & Koutnik, A. P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00694.2023 · Cited by 8
All-cause mortality and factors associated with it in Finnish patients with type 1 diabetes
Putula, E., Kauppala, T., Vanhamäki, S., Haapakoski, J., Laatikainen, T. K., & Metso, S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108881 · Cited by 14
Bombaci, B., Passanisi, S., Longo, A., Aramnejad, S., Rigano, F., Marzà, M. C., Formica, T., Pecoraro, M., Lombardo, F., & Salzano, G. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109142 · Cited by 8
Association of glycemic variability and time in range with lipid profile in type 1 diabetes
Castelo, M. I. S., Neves, C., Neves, J. S., & Carvalho, D. M. (2023) · Endocrine · doi:10.1007/s12020-023-03464-x · Cited by 12
Barranco-Altirriba, M., Rossell, J., Alonso, N., Weber, R. J. M., Ortega, E., Lloyd, G. R., Hernandez, M., Yanes, Ó., Capellades, J., Winder, C. L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02701-z · Cited by 9
Kim, H., Jung, D. Y., Lee, S., Cho, J., Yim, H. W., & Kim, H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e24 · Cited by 8
Autoimmune diseases and their prevalence in Saudi Arabian patients with type 1 diabetes mellitus
Mohammedsaeed, W. M., & Alghamdi, Z. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.8.20230240 · Cited by 7
Serés‐Noriega, T., Viñals, C., Perea, V., Mesa, A., Boswell, L., Mariaca, K., Blanco, J., Vinagre, I., Pané, A., Milad, C., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3783 · Cited by 9
Mallone, R., Bismuth, É., Thivolet, C., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., Beltrand, J., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.06.003 · Cited by 11
Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes
Teleb, M., Popp, M., Elhanafi, S. E., Elfar, A., & Juan, Z. T. S. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0700-6 · Cited by 8
Heller, T., Kloos, C., Lehmann, T., Schiel, R., Lorkowski, S., Wolf, G., Müller, U. A., & Muller, N. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-113452 · Cited by 9
Nyström, T., James, S. K., Lindahl, B., Östlund, O., Erlinge, D., Herlitz, J. D., Ömerovic, E., Mellbin, L., Alfredsson, J., Fröbert, O., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0590 · Cited by 7
Risk factors of death in diabetes mellitus
Asfandiyarova, N. S. (2016) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2016-94-9-697-700 · Cited by 7
Patton, S. R., Feldman, K., Majidi, S., Noser, A. E., & Clements, M. A. (2021) · Diabetic Medicine · doi:10.1111/dme.14637 · Cited by 9
Self-citationMalladi, N., Johny, E., Uppulapu, S. K., Tiwari, V., Alam, M. J., Adela, R., & Banerjee, S. K. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6404438 · Cited by 8
Toyoshima, M. T. K., Santana, M. D. F. M., da Silva, A. R. M., Mello, G. B., Santos‐Bezerra, D. P., Góes, M. F. S., Bosco, A., Caramelli, B., Ronsein, G. E., Corrêa‐Giannella, M. L., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01007-y · Cited by 7
“Background Type 1 diabetes (T1D) represents 5% to 10% of all diabetes cases [1] with an overall cardiovascular disease (CVD) risk—mainly manifested by coronary heart disease, cerebrovascular and peripheral artery disease—increased up to eight times in comparison to people without diabetes [2].”
BackgroundThe epidemiology of type 1 diabetes: Helping to fit the puzzle pieces
Forga, L. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.02.011 · Cited by 7
Melin, E. O., Hillman, M., Thunander, M., & Landin‐Olsson, M. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0481-3 · Cited by 9
The Streetlight Effect—Is There Light at the End of the Tunnel?
Lernmark, Å. (2015) · Diabetes · doi:10.2337/db15-0011 · Cited by 7
Epidemiology of Type 1 Diabetes
Stene, L. C., & Tuomilehto, J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch3 · Cited by 10
ENTPD3-specific CAR regulatory T cells for local immune control in T1DPreprint
Pieper, T., Riët, T., Saetzler, V., Bergerhoff, K. F., McGovern, J. L., Delsing, L., Atkinson, M. A., Lodie, T. A., Jermutus, L., Noyan, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.622951 · Cited by 8
Hals, I. K., Balasuriya, C. N. D., Casas, R., Ludvigsson, J., Björklund, A., & Grill, V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15239 · Cited by 8
Kim, J. Y., Kim, S., Park, S. H., Lee, J. A., Cho, S. H., Oh, R., Jang, M., Lee, Y., Kim, G., Hur, K. Y., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112325 · Cited by 7
Brännvall, R., Forsgren, H., Linge, H. M., Santini, M., Salehi, A., & Rahimian, F. (2022) · Swedish Artificial Intelligence Society Workshop (SAIS) · doi:10.1109/sais55783.2022.9833062 · Cited by 6
Hodnekvam, K., Iversen, H. H., Gani, O., Brunborg, C., & Skrivarhaug, T. (2023) · Diabetic Medicine · doi:10.1111/dme.15091 · Cited by 6
Wibæk, R., Ibfelt, E. H., Andersen, G. S., Hulmán, Á., Dabelea, D., Jørgensen, M. E., Svensson, J., Vistisen, D., & Rønn, P. F. (2023) · Diabetic Medicine · doi:10.1111/dme.15275 · Cited by 6
Lu, T., Manousaki, D., Sun, L., & Paterson, A. D. (2025) · Diabetes · doi:10.2337/db24-0380 · Cited by 9
Diabetic Kidney Disease: Much Progress, But Still More to Do
Molitch, M. E. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.154 · Cited by 6
Piniés, J. A., González-Carril, F., & Arteagoitia, J. M. (2015) · Avances en Diabetología · doi:10.1016/j.avdiab.2015.02.001 · Cited by 14
Association between dairy intake, lipids and vascular structure and function in diabetes
Petersen, K. S., Keogh, J. B., Lister, N. B., Weir, J. M., Meikle, P. J., & Clifton, P. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.202 · Cited by 8
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177283 · Cited by 7
Fang, F., Wang, N., Yan, S., Wang, L., Lu, Y., Li, J., Li, H., Pham, G., Li, C., Leng, S. X., et al. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.01.004 · Cited by 6
SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
Maj-Podsiadło, A., Cichocka, E., & Gumprecht, J. (2020) · Clinical Diabetology · doi:10.5603/dk.2020.0013 · Cited by 6
Maio, A., Maiorino, M. I., Longo, M., Scappaticcio, L., Pernice, V., Cirillo, P., Caruso, P., Paglionico, V. A., Bellastella, G., & Esposito, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac316 · Cited by 6
Haas, J., Franko, M. A., Olinder, A. L., Nyström, T., & Persson, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110899 · Cited by 9
Mesa, A., Giménez, M., Perea, V., Serés‐Noriega, T., Boswell, L., Blanco, J., Milad, C., Pané, A., Esmatjes, E., Vinagre, I., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3785 · Cited by 7
Lacigová, S., Brožová, J., Cechurová, D., Tomešová, J., Krčma, M., & Rušavý, Z. (2016) · Biomedical Papers · doi:10.5507/bp.2015.063 · Cited by 8
Marino, M., Eckert, A. J., Tell, S. S., Krnić, N., Deja, G., Rasmussen, V. F., Coelho, R. C. L. A., Todorovic, S., Jefferies, C., Sherif, E. M., et al. (2021) · Nutrients · doi:10.3390/nu13124473 · Cited by 6
Campbell, M. D., West, D. J., O’Mahoney, L. L., Pearson, S. M., Kietsiriroje, N., Holmes, M. J., & Ajjan, R. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01015-1 · Cited by 8
Söbü, E., Yenigürbüz, F. D., Özçora, G. D. K., & Köle, M. T. (2022) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmac063 · Cited by 6
Duman, B., Sariboyaci, A. E., & Karaöz, E. (2022) · Tissue & Cell · doi:10.1016/j.tice.2022.101919 · Cited by 4
Serés‐Noriega, T., Ortega, E., Perea, V., Giménez, M., Boswell, L., Mariaca, K., Font, C., Mesa, A., Viñals, C., Blanco, J., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01372-x · Cited by 6
Moving the Goalposts: Do Adults With Type 1 Diabetes Want Time in Tight Range?
Tanenbaum, M. L., Pasmooij, M. B., Tam, R., Basina, M., Hughes, M. S., Bishop, F. K., & Maahs, D. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.03.006 · Cited by 5
The Virtual DCCT #3: Relationship of HbA1c and CGM Metrics with Cardiovascular Outcomes
Horton, W. B., Kovatchev, B. P., Kanapka, L. G., & Beck, R. W. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251369538 · Cited by 5
Chen, Y., Tang, Y., Yue, R., Yang, B., Wang, A., Long, Y., Xu, Y., & Gao, C. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70111 · Cited by 5
Analyzing Random Forest’s Predictive Capability for Type 1 Diabetes Progression
Cleymans, N. F., de Casteele, M. V., Vandewalle, J., Desouter, A. K., Gorus, F., & Barbé, K. (2025) · IEEE Open Journal of Instrumentation and Measurement · doi:10.1109/ojim.2025.3551837 · Cited by 11
Gao, H., Zhao, Q., Tang, S., Li, K., Qin, F., Song, Z., Pan, Y., Jin, L., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83201-4 · Cited by 5
JENDLE, J. H., Ampudia‐Blasco, F. J., Füchtenbusch, M., & Pozzilli, P. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.12 · Cited by 6
“SGLT inhibitors in people with T1D improve glycaemic control and weight while reducing insulin doses without increasing the risk of hypoglycaemia.(61) Figure 6: Ketone monitoring levels and action required56”
BackgroundMelin, E. O., Svensson, R., Dereke, J., & Hillman, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.672931 · Cited by 7
“Other factors previously linked to cardiovascular disease and mortality are metabolic disturbances (13, 33, 34), T1D (35), physical inactivity (36), smoking (37), depression (38), and anxiety (39).”
BackgroundInfluentialMomani, A., Callery, P., Lin, Y., Abdelkader, R. H., & Akash, H. Y. A. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220214114908 · Cited by 5
Phowira, J., Ahmed, F. W., Bakhashab, S., & Weaver, J. U. (2022) · Biomedicines · doi:10.3390/biomedicines10092136 · Cited by 6
Horton, W. B., & Snell‐Bergeon, J. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad019 · Cited by 4
Honda, T., Kazemiparkouhi, F., & Suh, H. H. (2023) · Toxics · doi:10.3390/toxics11040336 · Cited by 5
Perea, V., Vinagre, I., Serés‐Noriega, T., Viñals, C., Mesa, A., Pané, A., Milad, C., Esmatjes, E., Conget, I., Giménez, M., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad755 · Cited by 6
Liarakos, A. L., Hasan, N. E., Crabtree, T. S. J., Leelarathna, L., Hammond, P. J., Hussain, S., Haq, M., Aslam, A., GATDULA, E. R., Gibb, F. W., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111597 · Cited by 5
Biasio, M. J. D., Furman, M., Clarke, A. B. M., Hui, W., Elia, Y. T., Baranger, J., Villemain, O., Mertens, L., & Mahmud, F. H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02280-5 · Cited by 7
Novel therapies for T1D on the horizon
Nasr, M. B., & Fiorina, P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.019 · Cited by 6
Paes, V. M., Charalampopoulos, D., Khanolkar, A. R., Taylor-Robinson, D. C., Viner, R., Edge, J., Stephenson, T. J., & Amin, R. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0146-8 · Cited by 5
Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes
Ganda, O. P., & Mitri, J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0790-1 · Cited by 6
Zucchini, S., Fabi, M., Maltoni, G., Zioutas, M., Trevisani, V., Natale, V. D., Cassio, A., & Pession, A. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01537-1 · Cited by 6
Neubauer‐Geryk, J., Wielicka, M., Kozera, G., Myśliwiec, M., Zorena, K., & Bieniaszewski, L. (2020) · Physiological Reports · doi:10.14814/phy2.14518 · Cited by 6
“However, mortality from type 1 diabetes is still increased two to eightfold when compared to general population (Lind et al., 2014; Rawshani et al., 2017), which reflects a loss of about 12 years of life expectancy at age 20.”
BackgroundLizarzaburu-Robles, J. C., Ortiz, J. M. V., Asociación para la prevención, E. E. I. E. D. A. L., & Gonzales, S. G. C. (2020) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2020.v20n4.14 · Cited by 7
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.